so is this the cost of percieved risk of Stevens-Johnson syndrome any time a rash is observed, or is this the cost of percieved risk of JNJ dropping out?
MRK was just warned.
"rash was not observed with boceprevir, GI side effects were the most common reason to discontinuation of the drug. The rate of discontinuation due to AEs was 9-12%, vs. 11-13% for telaprevir."
Market Data 
Markets 
AI
